DATA GRAPHICS | Data Byte
Ocrevus on top: How Roche is dominating MS sales
Multiple sclerosis therapy out-earning the competition by more than double
May 23, 2022 11:01 PM UTC
Roche’s Ocrevus continues to gain multiple sclerosis market share and has brought in more than double the revenue of its closest competitor for two quarters in a row.
Ocrevus ocrelizumab, an intravenously administered humanized anti-CD20 mAb from Roche (SIX:ROG; OTCQX:RHHBY), has led the market in global MS sales since 3Q20. It is Roche’s top-selling therapy, bringing in over $1.5 billion in sales in 1Q22. The therapy is approved to treat both the relapsing-remitting and primary-progressive forms of multiple sclerosis...